Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer

Four out of ten patients did not receive consolidation durvalumab mainly due to disease progression. Even among patients who initiated durvalumab, many patients relapsed and were retreated with ICIs. These findings underscore the need to refine treatment strategies for better outcomes in stage III unresectable NSCLC.

Authors

Jerome H. Goldschmidt
Ashwini Arunachalam (ORCID: https://orcid.org/0000-0003-4879-4770)
Paul Conkling (ORCID: https://orcid.org/0009-0002-9501-4482)
John Murphy (ORCID: https://orcid.org/0000-0003-0200-7778)
Sneha Sura

Institutions

Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
The US Oncology Network (US)

Publication Details

Journal: PLoS ONE
Published: 2024-11-25
DOI: https://doi.org/10.1371/journal.pone.0314156
Citations: 2
Primary Topic: Lung Cancer Diagnosis and Treatment
Type: article
Field-Weighted Citation Impact: 0.84

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer

Jerome H. Goldschmidt, Ashwini Arunachalam, Paul Conkling, John Murphy et al.

Nov 25, 2024

2 citations

PLoS ONE

Lung Cancer Diagnosis and Treatment

0.84

article

Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer

Jerome H. Goldschmidt, Ashwini Arunachalam, Paul Conkling, John Murphy, Sneha Sura

November 25, 2024article en

2 citations

Abstract

Four out of ten patients did not receive consolidation durvalumab mainly due to disease progression. Even among patients who initiated durvalumab, many patients relapsed and were retreated with ICIs. These findings underscore the need to refine treatment strategies for better outcomes in stage III unresectable NSCLC.

PLoS ONEVol. 19(11)

Merck & Co., Inc., Rahway, NJ, USA (United States) (US), The US Oncology Network (US)

Good health and well-being

Openalex Percentile: Top 23%

Lung Cancer Diagnosis and Treatment

0.84

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Real-world treatment patterns and outcomes among unresectable stage III non-small cell lung cancer — Jerome H. Goldschmidt, Ashwini Arunachalam, et al. · PLoS ONE (2024) | TGRS Research Map | TGRS